UK Confirms Its Leadership Position in Advanced Therapies

WASHINGTON, D.C. and LONDON, UK – July 18, 2019

Cell and gene therapies and tissue-engineered products have the potential to offer a durable, life-changing effect, possibly with single administration

New report from Alliance for Regenerative Medicine and UK BioIndustry Association highlights progress in financing and clinical trials

24% of Europe’s ATMP developers headquartered in the UK


The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector, and the BioIndustry Association (BIA), the trade association for innovative enterprises involved in UK bioscience, have today published a report setting out the scope of the UK’s robust and growing Advanced Therapy Medicinal Products (ATMPs) sector which includes the development of potentially transformative cell and gene therapies.

Key highlights include:

  • Financings for ATMP companies grew 66% from £473M to £785M between 2017 and 2018 and stand at £347M for 2019 year to date
  • More than 70 ATMP developers are active in the UK, including 56 headquartered in the country
  • Ninety-three ATMP clinical trials are ongoing in the UK, including 27 sponsored by UK companies

According to the report, the UK is a leading source of innovation and development of advanced therapy medicinal products (ATMPs) in Europe. These products, which include gene therapies, cell therapies, and tissue-engineered products, are intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes within the body. These therapies have the potential to provide profound and durable responses—often with just a single treatment—for patients with a diverse array of serious diseases and disorders.

However, despite the strength of the UK sector, the report highlights the need for policymakers and other stakeholders to promote a positive scientific, regulatory, and reimbursement environment to ensure that patients are able to access these products in a timely manner.

Janet Lambert, CEO of ARM, commented: “Advanced therapy products are already on the market in the UK for some haematological malignancies, as well as certain rare genetic disorders. Going forward, we expect to see cell and gene therapies approved for additional rare diseases and solid tumours, and for diseases with larger patient populations, including additional cancers, cardiovascular indications, and certain neurodegenerative disorders, such as Alzheimer’s and Parkinson’s.

“Our priority is driving the necessary financial and commercial innovation needed to ensure that patients are able to access these transformative therapies. We are committed to continuing our work with policymakers, industry, and other stakeholders to ensure this sector continues to push forward.”

Steve Bates OBE, CEO of the BIA, said: “This is an extraordinarily exciting time in medical research as advances in biology, technology, and data science open up new frontiers in the treatments of disease. The UK has already played a major role in the development of cell and gene therapies, establishing itself as a leader in this field, however, as with any innovation, the need for cell and gene therapies risks outpacing society’s and government’s capacity to adopt them. The UK needs the right infrastructure, talent, and regulation in place to continue to be a leader in this space.  We need the commitment from all parts of the ecosystem to address potential barriers to the growth of the industry and to ensure that these treatments reach patients who will benefit from them.” 

A copy of the full report can be accessed here.

Recommendations to continue driving ATMP development in the UK:
  • Support scientific research to develop and advance both ATMPs and ancillary processes, including manufacturing and scale up.
  • Foster economic development and the creation of a skilled workforce to promote the continued growth of this industry in the UK.
  • Cultivate a positive regulatory environment for the research and development of ATMPs, including fostering accelerated pathways to ensure that patients are able to access safe and effective therapies in a timely manner.
  • Develop the necessary infrastructures within NICE and its counterparts in Scotland, Wales, and Northern Ireland to ensure health technology assessments are able to address the long-term value provided by ATMPs.
  • Collaborate with the NHS and other public and private payers in the UK to develop innovative financing models to ensure patients can access approved therapies in an efficient manner.

Press enquiries

For more information about the report or media requests, please contact Lyndsey Scull from the Alliance for Regenerative Medicine at, Jack Fellows from the BIA at, or Consilium Strategic Communications at


About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. Founded in 2009, ARM works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its 330+ member organizations worldwide. ARM represents the interests of therapeutic developers, academic research institutions, major medical centres, investors, and patient groups that comprise the broader regenerative medicine community and is the prominent international advocacy organization in this field.

ARM has 70+ members across 15 countries in Europe.ARM aims to work closely with European stakeholders, leveraging its membership to create a supportive commercial and regulatory environment to create better conditions for the development and commercialization of ATMPs in Europe; develop strong stakeholder support around proposed solutions to improve patient access to ATMPs; promote clear, predictable and efficient regulatory framework across Europe; and promote international convergence of key regulations and guidances. For more information, visit


About the BioIndustry Asscoiation

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.

For further information, please go to and